FY2026 EPS Forecast for Bristol Myers Squibb Cut by Analyst

Bristol Myers Squibb Company (NYSE:BMY) – Equities researchers at Zacks Research dropped their FY2026 earnings estimates for Bristol Myers Squibb in a note issued to investors on Wednesday, November 11th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of $6.44 per share for the year, down from their previous forecast of $6.86. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.46 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s Q4 2026 earnings at $1.47 EPS, Q2 2027 earnings at $1.70 EPS, Q4 2027 earnings at $1.56 EPS and FY2028 earnings at $4.77 EPS.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The company had revenue of $13.07 billion for the quarter, compared to analysts’ expectations of $12.72 billion. During the same period in the prior year, the company posted $1.63 EPS. Bristol Myers Squibb’s revenue was up 6.9% compared to the same quarter last year.

BMY has been the subject of several other reports. Piper Sandler reduced their price target on Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating for the company in a research report on Monday, October 26th. Citigroup reissued a “neutral” rating and set a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Roth Capital initiated coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating and a $75.00 target price for the company. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 19th. Finally, Raymond James Financial began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and an average price target of $65.46.

Bristol Myers Squibb Trading Down 0.8%

Shares of BMY stock opened at $62.42 on Friday. The stock has a market capitalization of $127.58 billion, a price-to-earnings ratio of 13.84, a PEG ratio of 0.32 and a beta of 0.20. The company’s fifty day simple moving average is $61.99 and its two-hundred day simple moving average is $60.27. Bristol Myers Squibb has a 1 year low of $45.26 and a 1 year high of $68.64. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pinion Investment Advisors LLC lifted its stake in Bristol Myers Squibb by 3.8% during the third quarter. Pinion Investment Advisors LLC now owns 4,316 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 158 shares during the last quarter. Altura Wealth Advisors Inc. increased its position in shares of Bristol Myers Squibb by 1.2% during the 3rd quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company’s stock valued at $856,000 after purchasing an additional 161 shares during the last quarter. Capital City Trust Co. FL raised its holdings in shares of Bristol Myers Squibb by 0.7% during the 3rd quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company’s stock valued at $1,455,000 after buying an additional 167 shares in the last quarter. Eagle Bay Advisors LLC raised its holdings in shares of Bristol Myers Squibb by 2.6% during the 3rd quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company’s stock valued at $408,000 after buying an additional 168 shares in the last quarter. Finally, Blue Bell Private Wealth Management LLC lifted its position in Bristol Myers Squibb by 21.1% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 969 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 169 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Bristol Myers Squibb

In other Bristol Myers Squibb news, Director Julia A. Haller sold 3,800 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the transaction, the director owned 30,279 shares of the company’s stock, valued at $1,916,963.49. The trade was a 11.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their position. The SEC filing for this sale provides additional information. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. Bristol Myers Squibb’s payout ratio is presently 55.88%.

Trending Headlines about Bristol Myers Squibb

Investors following BMY have been watching these headlines:

• Positive Sentiment: Some analysts and commentators consider BMY attractively valued, citing roughly 10 times forward earnings and a view that shares remain below fair value despite a strong multi-year run. That could support investor interest if the company delivers on its cash-flow and pipeline prospects. Our Bristol Myers Squibb Stock Pick Is Up 35%. It’s Still a Good Bet in Healthcare. Bristol Myers Squibb Stock Looks Below Fair Value Following A 41% Run
• Neutral Sentiment: Bristol Myers plans to bring its scientific and clinical teams together in a unified R&D organization, aiming to accelerate development and make better use of new technologies. Research chief Robert Plenge is leaving as part of the change. The strategy could improve productivity, but the leadership transition and results of the restructuring remain uncertain. Bristol Myers to merge scientific, clinical teams under new R&D structure Bristol Myers research chief to depart in evolution of company’s structure
• Negative Sentiment: Drug-price negotiations are a potential longer-term headwind for BMY, with the article describing the company as facing a bigger test in the years ahead. The risk is not presented as an immediate revenue hit, but could weigh on future pricing and growth expectations. Drug pricing risks for pharmaceutical companies

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.